Nurix Therapeutics Inc (NASDAQ:NRIX) has a beta value of 2.10 and has seen 1.51 million shares traded in the last trading session. The company, currently valued at $713.03M, closed the last trade at $12.02 per share which meant it lost -$0.45 on the day or -3.61% during that session. The NRIX stock price is -50.75% off its 52-week high price of $18.12 and 64.89% above the 52-week low of $4.22. The 3-month trading volume is 1.03 million shares.
Nurix Therapeutics Inc (NASDAQ:NRIX) trade information
Sporting -3.61% in the red in last session, the stock has traded in the red over the last five days, when the NRIX stock price touched $12.02 or saw a rise of 16.64%. Year-to-date, Nurix Therapeutics Inc shares have moved 16.47%, while the 5-day performance has seen it change -14.93%. Over the past 30 days, the shares of Nurix Therapeutics Inc (NASDAQ:NRIX) have changed -17.56%.
Nurix Therapeutics Inc (NRIX) estimates and forecasts
Figures show that Nurix Therapeutics Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 173.18% over the past 6 months, with this year growth rate of -18.87%, compared to 12.60% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are -48.90% and -8.80% for the next quarter. Revenue growth from the last financial year stood is estimated to be -3.60%.
7 analysts offering their estimates for the company have set an average revenue estimate of $23.44 million for the current quarter. 7 have an estimated revenue figure of $17.88 million for the next quarter concluding in Aug 2024.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -59.00% over the past 5 years.
NRIX Dividends
Nurix Therapeutics Inc is expected to release its next earnings report in June this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
